In medical school, I met a young woman with severe psoriasis, obesity, and hyperlipidemia, who pointed to plaques padding her knees. I learned she skipped school because the lesions embarrassed her. Further questions revealed heart attacks ran in her family. I asked more questions about her family history of heart disease until she snapped, “why does that matter here?” Our young patient deepened my interest in disorders like psoriasis, systemic lupus erythematosus (SLE), and dermatomyositis – multi-system, inflammatory disorders in medical dermatology that elevate cardiovascular (CV) risk [1–3]. I informed her that inflammation in psoriasis may exacerbate or accelerate atherosclerotic CV disease (ASCVD) independent of traditional CV risk factors [4].

Psoriasis, lupus, and dermatomyositis patients suffer from a greater proportion of heart attacks and strokes compared to rates in the general population. Under-recognition and undertreatment of traditional CV risk factors, including smoking, hyperlipidemia, and hypertension in these populations, presents a significant problem in and of itself [5,6]. Common ASCVD risk estimation tools like the Pooled Cohorts Equations may underestimate CV risk in patients with inflammatory disease. The need to perform targeted screening, consider appropriate risk calculators, and implement care models for inflammatory disorders including but not limited to psoriasis, lupus, and dermatomyositis remains critical [7]. In this fellow’s voice, I will briefly overview and call attention to the intersection among psoriasis, lupus, and dermatomyositis with CVD.

In psoriasis, one of the more well-studied inflammatory disorders in cardiology, significant gains have been made to evaluate and lower CV risk. In the last decade, low-density granulocytes, a type of neutrophil, were identified as an immune cell promoting early, high-risk coronary plaque formation [8]. Traditional CV risk factors, including hyperlipidemia (46%), hypertension (42%), type 2 diabetes (18%), and obesity (14%) have been reported in a large cohort of 467,097 patients with psoriasis [9]. This work follows several endpoint studies, including a landmark one showing a three times higher risk of myocardial infarction (MI) in young patients with severe psoriasis compared to the rate in the generation population [10].

In 2019, the American Academy of Dermatology and the National Psoriasis Foundation released recommendations to address cardiometabolic disease in patients with psoriasis with an emphasis on early, aggressive CV risk factor screening and modification [11]. That same year, the American College of Cardiology (ACC) and American Heart Association (AHA) guideline on primary prevention of CVD recognized psoriasis in a category of inflammatory diseases, along with HIV, lupus, and rheumatoid arthritis. As a risk enhancer of ASCVD, psoriasis may warrant earlier initiation of a statin in patients with lower ASCVD risk scores [12]. Interestingly, a prospective, observational trial in patients with severe psoriasis showed one year of biologic therapy reduced total and non-calcified coronary plaque burden by 8%, on par with the effect of a low-dose statin [13].

In lupus, a disorder that disproportionately affects women, CVD outcomes include not only ASCVD, but also pericarditis, vasculitis, and antiphospholipid syndrome. An increased prevalence of CV risk factors, including dyslipidemia, obesity, diabetes, hypertension, and metabolic syndrome, has been reported in patients with lupus compared to those in the general population [14]. The risk of MIs was elevated in patients with systemic manifestations (SLE) as well as in patients with cutaneous manifestations (CLE). A pooled meta-analysis showed a three times higher risk of MI and two times higher risk of stroke in patients with SLE [15]. The more striking observation pertains to women with SLE aged 35 to 44 years who may have a 50 times higher risk of MI than women of that age in the general population [16]. In patients with CLE, increased rates of ASCVD events have been reported compared to the general population but not as high as those of SLE [17].

These findings in SLE and CLE suggest a skin screening can be the first warning sign of CVD. It is thus imperative to recognize and
preemptively treat CV factors in SLE to lower ASCVD risk, especially considering overlooked sex disparities in CV outcomes. Statins, for example, are safe in lupus patients, and should be used as appropriate including in reproductive age women. While statins are generally still discontinued during pregnancy and breastfeeding (except in the highest risk cases), unintended exposure to statins early in pregnancy is unlikely to cause fetal harm. Thus, statins should not be avoided in women of child-bearing potential. The ACC/AHA guideline recognized SLE as a chronic inflammatory disease and risk enhancer for ASCVD management, which may be complicated by the need for systemic steroids and drug-drug interactions.

In dermatomyositis, a lesser-studied autoimmune disorder, ASCVD has been reported in both adults and children. Children with juvenile dermatomyositis present with elevated CV risk, including hypertension, obesity, uncomplicated diabetes, lipodystrophy, and stroke [18]. Serial CV management with labs and potential noninvasive imaging to monitor ASCVD progression may need to occur. In adults, the odds of having an MI in dermatomyositis were three times greater than odds in the general population [19]. Additionally, the rate of mortality from an ischemic CV management with labs and potential noninvasive imaging to monitor ASCVD progression may need to occur. In adults, the odds of having an MI in dermatomyositis were three times greater than odds in the general population [19]. Additionally, the rate of mortality from an ischemic atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis. Int J Womens Dermatol 2021.

References

[1] Miller Ben Marie, et al. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol 2013;69(6):1014–24.
[2] Giannouli Mayra, Mavragani Clio P. Cardiovascular disease in systemic lupus erythematosus: a comprehensive update. J Autoimmun 2017;82:1–12.
[3] Lundberg IE. The heart in dermatomyositis and polymyositis. Rheumatology 2006; 45(suppl 4):IV18–21.
[4] Weber Brittany, et al. Cardiovascular disease prevention in individuals with underlying chronic inflammatory disease. Curr Opin Cardiol 2021;36(5):549–55.
[5] Keyes Emily, et al. Assessment and management of the heightened risk for atheroclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis. Int J Womens Dermatol 2021.
[6] Yamasaki Fumikazu. Psoriasis: comorbidities. J Dermatol 2021;48(6):732–40.
[7] Yoo Bianca W. Embarking on a career in cardio-rheumatology. J Am Coll Cardiol 2020;75(13):1488–92.
[8] Garshick Michael S, et al. Cardiovascular risk in patients with psoriasis: JACC review topic of the week. J Am Coll Cardiol 2021;77(13):1670–80.
[9] Shah Kamal, et al. Real-world burden of comorbidities in US patients with psoriasis. J Am Acad Dermatol 2017;77(2):287–92.
[10] Gelfand Joel M, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296(14):1735–41.
[11] Eilsma-Craig A, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol 2019;80(4):1073–113.
[12] Arnett Donna K, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;140(11):e596–646.
[13] Elshawi Younsef A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriatic results from a prospective observational study. Cardiovasc Res 2019;115(4):721–8.
[14] Bessant Rupa, et al. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: a case-control study. Arthritis Care Res: Off J Am College Rheumatol 2006;55(6):892–9.
[15] Gu Ming-Ming, et al. A meta-analysis of cardiovascular events in systemic lupus erythematosus. Immunol Invest 2019;48(5):505–20.
[16] Manzi Susan, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145(5):408–15.
[17] Hesselvig JHalskou, et al. Cutaneous lupus erythematosus and systemic lupus erythematosus: a comprehensive update. J Autoimmun 2017;82:1.
[18] Silverberg Jonathan I, et al. Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample. Rheumatology 2018;57(4):694–702.
[19] Lai YT, et al. Dermatomyositis is associated with an increased risk of cardiovascular and cerebrovascular events: a Taiwanese population-based longitudinal follow-up study. Br J Dermatol 2013;168(5):1054–9.
[20] Jung KH, et al. Incidence, survival, and risk of cardiovascular events in adult inflammatory myopathies in South Korea: a nationwide population-based study. Scand J Rheumatol 2020;49(4):323–31.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Samip Sheth
Georgetown University School of Medicine, 3900 Reservoir Rd NW, Washington, DC 20007, USA
E-mail address: ss4355@georgetown.edu.